(2R)-2-amino-2-(1-sulfanylcyclopentyl)acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-amino-2-(1-sulfanylcyclopentyl)acetic acid
• 化学式: C₇H₁₃NO₂S
• 分子量: 175.25
• InChiKey: KAXJPSGVJZVTJK-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing
  申请人：——

  公开号：US20030065146A1

  公开（公告）日：2003-04-03

  Novel ethylene glycol compounds bearing various functional groups are used to prepare oligomeric structures. The ethylene glycol monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.

  新型乙二醇化合物带有各种功能基团，用于制备寡聚体结构。乙二醇单体可以通过标准的磷酸酯和磷酸硫酯键连接。有用的功能基团包括核苷碱以及极性基团，疏水基团，离子基团，芳香基团和/或参与氢键的基团。
• Compounds and methods for modulating nonclassical cadherin-mediated functions
  申请人：Adherex Technologies, Inc.

  公开号：EP1970383A1

  公开（公告）日：2008-09-17

  Modulating agents for inhibiting or enhancing nonclassical cadherin mediacted cell adhesion are provided.

  本研究提供了用于抑制或增强非经典凝集素介导的细胞粘附性的调节剂。
• Compounds that modulate neuronal growth and their uses
  申请人：Wyeth LLC

  公开号：EP2438925A2

  公开（公告）日：2012-04-11

  Cyclic peptides and peptidomimetics are provided that bind to and/or modulate activities associated with Trk receptors, including processes associated with the growth and repair of the central nervous system (e.g., neuronal growth and survival, axonal growth, neurite outgrowth and synaptic plasticity). Cyclic peptides and peptidomimetics are also provided that block or reduce the effect of other factors that inhibit growth and/or repair of the central nervous system. Pharmaceutical compositions and other formulations comprising these compounds are provided. In addition, the invention provides methods for using the cyclic peptides and peptidomimetics to modulate Trk mediated activities, including processes such as neuronal growth, survival and recover, axonal growth, neurite outgrowth, and synaptic plasticity. Further, the invention provides methods for promoting central nervous system (CNS) neuron growth by administering a p75 receptor binding agent.

  提供的环肽和多肽模拟物能与 Trk 受体结合和/或调节与 Trk 受体相关的活动，包括与中枢神经系统生长和修复相关的过程（如神经元生长和存活、轴突生长、神经元突起和突触可塑性）。环肽和拟肽还能阻断或减少抑制中枢神经系统生长和/或修复的其他因素的作用。本发明还提供了包含这些化合物的药物组合物和其他制剂。此外，本发明还提供了使用环肽和拟肽物调节 Trk 介导的活动的方法，包括神经元生长、存活和恢复、轴突生长、神经元突起和突触可塑性等过程。此外，本发明还提供了通过施用 p75 受体结合剂促进中枢神经系统（CNS）神经元生长的方法。
• CXCR antagonistic peptides and uses thereof
  申请人：STC.UNM

  公开号：US10548942B2

  公开（公告）日：2020-02-04

  The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

  本发明提供了一类基于 CXCR 拮抗肽的新型药物。除其他外，本发明还提供了用于治疗涉及 CXCR 介导途径的疾病、失调和病症的多肽、组合物和方法。本发明提供了有效治疗炎症、中风、创伤性脑损伤、胰腺癌等疾病的组合物和方法。
• Methods and compositions for the treatment of epidermolysis bullosa
  申请人：Constant Therapeutics LLC

  公开号：US10960045B2

  公开（公告）日：2021-03-30

  A method of treating epidermolysis bullosa comprising administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide is described. In some embodiments, methods of treating a complication of epidermolysis bullosa are described including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.

  描述了一种治疗大疱性表皮松解症的方法，该方法包括向患有大疱性表皮松解症的受试者施用血管紧张素（1-7）肽。在一些实施方案中，描述了治疗大疱性表皮松解症并发症的方法，包括向患有大疱性表皮松解症的一种或多种并发症的受试者施用血管紧张素（1-7）肽，其中施用血管紧张素（1-7）肽可降低大疱性表皮松解症的一种或多种并发症的至少一种症状或特征的强度、严重程度、持续时间或频率。